Canton Strategic Holdings (CNTN) Income from Continuing Operations (2021 - 2026)
Canton Strategic Holdings (CNTN) posted Income from Continuing Operations of 47343197.0 for Q1 2026, down 248.26% on a QoQ basis from 13594306.0 in Q4 2025, and down 1762.66% year-over-year from 2847444.25 in Q1 2025.
Canton Strategic Holdings (CNTN) Income from Continuing Operations (2021 - 2026) Analysis & Trends
Canton Strategic Holdings' Income from Continuing Operations history runs 6 years deep, the most recent figure standing at 47343197.0 for Q1 2026.
- Quarterly Income from Continuing Operations fell 1762.66% year-over-year to 47343197.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 64894494.0 (down 421.27% YoY) and the FY2025 annual result came in at 42942836.0, down 252.06% from the prior year.
- Income from Continuing Operations was 47343197.0 for Q1 2026 at Canton Strategic Holdings, down from 13594306.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 188679.0 in Q4 2022 and bottomed at 47343197.0 in Q1 2026.
- A 5-year average of 5636661.59 and a median of 2336914.0 in 2023 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2022 — Income from Continuing Operations surged 47.53% — and 2026, when it sank 1762.66%.
- Canton Strategic Holdings' Income from Continuing Operations stood at 188679.0 in 2022, then sank by 1211.1% to 2473777.0 in 2023, then plunged by 53.08% to 3786758.0 in 2024, then tumbled by 259.0% to 13594306.0 in 2025, then slumped by 248.26% to 47343197.0 in 2026.
- Business Quant data shows CNTN's Income from Continuing Operations at 47343197.0 in Q1 2026, 13594306.0 in Q4 2025, and 2101838.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Canton Strategic Holdings | 427.87 Mn | 427.87 Mn | - | -47.34 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -47.34 Mn |
| Dec 31, 2025 | -13.59 Mn |
| Sep 30, 2025 | -2.10 Mn |
| Jun 30, 2025 | -1.86 Mn |
| Mar 31, 2025 | -2.54 Mn |
| Dec 31, 2024 | -3.79 Mn |
| Sep 30, 2024 | -3.80 Mn |
| Jun 30, 2024 | -2.33 Mn |
| Mar 31, 2024 | -2.26 Mn |
| Dec 31, 2023 | -2.47 Mn |
| Sep 30, 2023 | -1.82 Mn |
| Jun 30, 2023 | -2.34 Mn |
| Mar 31, 2023 | -2.69 Mn |
| Dec 31, 2022 | -188,679.00 |
| Sep 30, 2022 | -2.13 Mn |
| Jun 30, 2022 | -1.64 Mn |
| Mar 31, 2022 | -2.95 Mn |
| Dec 31, 2021 | -359,593.00 |
| Sep 30, 2021 | -777,113.00 |
| Jun 30, 2021 | -1.29 Mn |